Brain distribution of cediranib is limited by active efflux at the blood-brain barrier

Journal of Pharmacology and Experimental Therapeutics

Volumn 341, Issue 2, 2012, Pages 386-395

  Wang, Tianli ^a   Agarwal, Sagar ^a   Elmquist, William F ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CEDIRANIB; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 1A; MULTIDRUG RESISTANCE PROTEIN 1B; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG PENETRATION; DRUG TRANSPORT; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PHASE PARTITIONING; PRIORITY JOURNAL; STEADY STATE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; BRAIN; CELL LINE; CELL MEMBRANE PERMEABILITY; DOGS; HUMANS; MICE; MICE, KNOCKOUT; P-GLYCOPROTEIN; QUINAZOLINES; TISSUE DISTRIBUTION;

EID: 84859974633     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.111.190488     Document Type: Article

References (30)

1. Agarwal S, Sane R, Gallardo JL, Ohlfest JR, and Elmquist WF (2010) Distribution of gefitinib to the brain is limited by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)-mediated active efflux. J Pharmacol Exp Ther 334:147-155.
2. Agarwal S, Sane R, Oberoi R, Ohlfest JR, and Elmquist WF (2011a) Delivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain. Expert Rev Mol Med 13:e17.
3. Agarwal S, Sane R, Ohlfest JR, and Elmquist WF (2011b) The role of the breast cancer resistance protein (ABCG2) in the distribution of sorafenib to the brain. J Pharmacol Exp Ther 336:223-233.
4. Batchelor TT, Duda DG, di Tomaso E, Ancukiewicz M, Plotkin SR, Gerstner E, Eichler AF, Drappatz J, Hochberg FH, Benner T, et al. (2010) Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol 28:2817-2823.
5. Batchelor TT, Sorensen AG, di Tomaso E, Zhang WT, Duda DG, Cohen KS, Kozak KR, Cahill DP, Chen PJ, Zhu M, et al. (2007) AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11:83-95. (Pubitemid 46075199)
6. Breedveld P, Pluim D, Cipriani G, Wielinga P, van Tellingen O, Schinkel AH, and Schellens JH (2005) The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients. Cancer Res 65:2577-2582. (Pubitemid 40490054)
7. Carmeliet P and Jain RK (2000) Angiogenesis in cancer and other diseases. Nature 407:249-257.
8. Chen Y, Agarwal S, Shaik NM, Chen C, Yang Z, and Elmquist WF (2009) P-glycoprotein and breast cancer resistance protein influence brain distribution of dasatinib. J Pharmacol Exp Ther 330:956-963.
9. Dai H, Marbach P, Lemaire M, Hayes M, and Elmquist WF (2003) Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux. J Pharmacol Exp Ther 304:1085-1092. (Pubitemid 36254421)
10. Demeule M, Régina A, Annabi B, Bertrand Y, Bojanowski MW, and Béliveau R (2004) Brain endothelial cells as pharmacological targets in brain tumors. Mol Neurobiol 30:157-183. (Pubitemid 41271214)
11. Gerstner ER, Chen PJ, Wen PY, Jain RK, Batchelor TT, and Sorensen G (2010) Infiltrative patterns of glioblastoma spread detected via diffusion MRI after treatment with cediranib. Neuro Oncol 12:466-472.
12. Giri N, Shaik N, Pan G, Terasaki T, Mukai C, Kitagaki S, Miyakoshi N, and Elmquist WF (2008) Investigation of the role of breast cancer resistance protein (Bcrp/Abcg2) on pharmacokinetics and central nervous system penetration of abacavir and zidovudine in the mouse. Drug Metab Dispos 36:1476-1484.
13. Hormigo A, Ding BS, and Rafii S (2011) A target for antiangiogenic therapy: vascular endothelium derived from glioblastoma. Proc Natl Acad Sci U S A 108:4271-4272.
14. Huang H, Held-Feindt J, Buhl R, Mehdorn HM, and Mentlein R (2005) Expression of VEGF and its receptors in different brain tumors. Neurol Res 27:371-377. (Pubitemid 40734696)
15. Institute of Laboratory Animal Resources (1996) Guide for the Care and Use of Laboratory Animals, 7th ed. Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council, Washington, DC.
16. Kamiie J, Ohtsuki S, Iwase R, Ohmine K, Katsukura Y, Yanai K, Sekine Y, Uchida Y, Ito S, and Terasaki T (2008) Quantitative atlas of membrane transporter proteins: development and application of a highly sensitive simultaneous LC/MS/MS method combined with novel in-silico peptide selection criteria. Pharm Res 25:1469-1483.
17. Kamoun WS, Ley CD, Farrar CT, Duyverman AM, Lahdenranta J, Lacorre DA, Batchelor TT, di Tomaso E, Duda DG, Munn LL, et al. (2009) Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice. J Clin Oncol 27:2542-2552.
18. Kodaira H, Kusuhara H, Ushiki J, Fuse E, and Sugiyama Y (2010) Kinetic analysis of the cooperation of P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone. J Pharmacol Exp Ther 333:788-796.
19. Kuratsu J, Itoyama Y, Uemura S, and Ushio Y (1989) [Regrowth patterns of glioma-cases of glioma regrew away from the original tumor]. Gan No Rinsho 35:1255-1260.
20. Lee YJ, Kusuhara H, Jonker JW, Schinkel AH, and Sugiyama Y (2005) Investigation of efflux transport of dehydroepiandrosterone sulfate and mitoxantrone at the mouse blood-brain barrier: a minor role of breast cancer resistance protein. J Pharmacol Exp Ther 312:44-52. (Pubitemid 40096451)
21. Lucio-Eterovic AK, Piao Y, and de Groot JF (2009) Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy. Clin Cancer Res 15:4589-4599.
22. Morelli MP, Brown AM, Pitts TM, Tentler JJ, Ciardiello F, Ryan A, Jürgensmeier JM, and Eckhardt SG (2009) Targeting vascular endothelial growth factor receptor-1 and -3 with cediranib (AZD2171): effects on migration and invasion of gastrointestinal cancer cell lines. Mol Cancer Ther 8:2546-2558.
23. Polli JW, Olson KL, Chism JP, John-Williams LS, Yeager RL, Woodard SM, Otto V, Castellino S, and Demby VE (2009) An unexpected synergist role of P-glycoprotein and breast cancer resistance protein on the central nervous system penetration of the tyrosine kinase inhibitor lapatinib (N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}- 6-[5-({[2-(methylsulfonyl)ethy l]amino}methyl)-2-furyl]-4-quinazolinamine; GW572016). Drug Metab Dispos 37:439-442.
24. Ramalingam SS, Belani CP, Mack PC, Vokes EE, Longmate J, Govindan R, Koczywas M, Ivy SP, and Gandara DR (2010) Phase II study of Cediranib (AZD 2171), an inhibitor of the vascular endothelial growth factor receptor, for second-line therapy of small cell lung cancer (National Cancer Institute #7097). J Thorac Oncol 5:1279-1284.
25. Satoh T, Yamaguchi K, Boku N, Okamoto W, Shimamura T, Yamazaki K, Shi X, and Mishima H (2011) Phase I results from a two-part Phase I/II study of cediranib in combination with mFOLFOX6 in Japanese patients with metastatic colorectal cancer. Invest New Drugs http://dx.doi.org/10.1007/s10637-011-9693-6.
26. Sikkema AH, de Bont ES, Molema G, Dimberg A, Zwiers PJ, Diks SH, Hoving EW, Kamps WA, Peppelenbosch MP, and den Dunnen WF (2011) Vascular endothelial growth factor receptor 2 (VEGFR-2) signalling activity in paediatric pilocytic astrocytoma is restricted to tumour endothelial cells. Neuropathol Appl Neurobiol 37:538-548.
27. Silbergeld DL and Chicoine MR (1997) Isolation and characterization of human malignant glioma cells from histologically normal brain. J Neurosurg 86:525-531. (Pubitemid 27097100)
28. Tang SC, Lagas JS, Lankheet NA, Poller B, Hillebrand MJ, Rosing H, Beijnen JH, and Schinkel AH (2012) Brain accumulation of sunitinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration. Int J Cancer 130:223-233.
29. Wang T, Oberoi RK, and Elmquist WF (2011) Determination of cediranib in mouse plasma and brain tissue using high-performance liquid chromatography-mass spectrometry, J Chromatogr B Analyt Technol Biomed Life Sci 879:3812-3817.
30. Zhao R, Raub TJ, Sawada GA, Kasper SC, Bacon JA, Bridges AS, and Pollack GM (2009) Breast cancer resistance protein interacts with various compounds in vitro, but plays a minor role in substrate efflux at the blood-brain barrier. Drug Metab Dispos 37:1251-1258.